Milestones :: Perspectives :: Research
New additions and recent updates
The Israel Institute for Biological Research moves to Phase 2.
Brazil announces Sinovac’s vaccine has an efficacy of just over 50 percent.
California-based Arcturus moves to Phase 2.
Canada’s VIDO enters Phase 1/.